Elutia (ELUT) Cash from Financing Activities (2019 - 2026)
Elutia (ELUT) reported Cash from Financing Activities of $3000.0 for Q1 2026, down 99.98% on a YoY basis from $13.3 million in Q1 2025, and up 100.01% sequentially from -$23.1 million in Q4 2025.
Elutia (ELUT) Cash from Financing Activities (2019 - 2026) Analysis & Trends
Elutia (ELUT) has 8 years of Cash from Financing Activities data on file, last reported at $3000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Financing Activities fell 99.98% year-over-year to $3000.0; the trailing twelve-month figure through Mar 2026 stood at -$23.9 million (down 169.43% YoY), and the FY2025 full-year result was -$10.6 million, down 162.23% from the prior year.
- Cash from Financing Activities grew to $3000.0 in Q1 2026, from -$23.1 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $14.3 million in Q4 2022 to a low of -$23.1 million in Q4 2025.
- A 5-year average of $1.4 million and a median of -$151000.0 in 2024 frame the typical range for Cash from Financing Activities.
- Across the five-year window, Cash from Financing Activities jumped 51610.53% in 2024 and tumbled 15223.18% in 2025, its largest moves.
- Tracing ELUT's Cash from Financing Activities over 5 years: stood at $14.3 million in 2022, then tumbled by 104.87% to -$695000.0 in 2023, then jumped by 78.27% to -$151000.0 in 2024, then plunged by 15223.18% to -$23.1 million in 2025, then soared by 100.01% to $3000.0 in 2026.
- Business Quant data shows ELUT's Cash from Financing Activities at $3000.0 in Q1 2026, -$23.1 million in Q4 2025, and -$262000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 17.31 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | -1.51 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | -888.00 Mn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | -260.00 Mn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | -451.20 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | -25.00 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | -26.93 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 21.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Elutia | 39.99 Mn | 11.50 Mn | 1.80 Mn | 3,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3,000.00 |
| Mar 31, 2026 | 3,000.00 |
| Dec 31, 2025 | -23.14 Mn |
| Dec 31, 2025 | -23.14 Mn |
| Sep 30, 2025 | -262,000.00 |
| Sep 30, 2025 | -262,000.00 |
| Jun 30, 2025 | -516,000.00 |
| Jun 30, 2025 | -516,000.00 |
| Mar 31, 2025 | 13.28 Mn |
| Mar 31, 2025 | 13.28 Mn |
| Dec 31, 2024 | -151,000.00 |
| Dec 31, 2024 | -151,000.00 |
| Sep 30, 2024 | 11.53 Mn |
| Sep 30, 2024 | 11.53 Mn |
| Jun 30, 2024 | 9.79 Mn |
| Jun 30, 2024 | 9.79 Mn |
| Mar 31, 2024 | -4.07 Mn |
| Mar 31, 2024 | -4.07 Mn |
| Dec 31, 2023 | -695,000.00 |
| Dec 31, 2023 | -695,000.00 |